Veracyte Decipher Prostate test predicts benefit of adding hormone therapy to radiation in Phase III trial analysis

• Veracyte flagged new Decipher Prostate test data from a retrospective analysis of the phase III NRG/RTOG 0815 trial.
• Results will be presented at the ASTRO Annual Meeting on Sept. 29, 2026.
• Study found the test identified intermediate-risk patients likely to gain meaningful benefit from adding short-term hormone therapy to radiation.
• Patients with low-risk genomic profiles showed little added benefit, supporting potential treatment de-intensification to avoid hormone-therapy side effects.
• Findings broaden Decipher’s role from risk assessment to treatment selection, reinforcing its strategic value in the intermediate-risk care pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290800PRIMZONEFULLFEED9835642) on September 29, 2026, and is solely responsible for the information contained therein.